← Back to Treatments
🏅 FDA Orphan Designation

Acetylcysteine

ACETYLCYSTEINE

Manufacturer: Hospira, Inc.

Indicated for:
Paracetamol poisoningMounier-Kühn syndromePulmonary arterial hypertension associated with another diseaseIdiopathic bronchiectasisPneumoconiosisB-cell chronic lymphocytic leukemiaPlastic bronchitisCystic fibrosisAccessory pancreasComplication in hemodialysisOBSOLETE: Posttraumatic hypopituitarismSelective intrauterine growth restrictionTuberculosisGelatinous drop-like corneal dystrophy

FDA-Approved Indications (14)

indicated as an antidote to prevent or lessen hepatic injury which may occur following the ingestion of a potentially hepatotoxic quantity of acetaminophen

Population: all ages

adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in tracheobronchitis

Population: all ages

adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in pulmonary complications associated with surgery

Population: all ages

adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in bronchiectasis

Population: all ages

adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in pneumonia

Population: all ages

adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in chronic emphysema

Population: all ages

adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in emphysema with bronchitis

Population: all ages

adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in pulmonary complications of cystic fibrosis

Population: all ages

adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in tracheostomy care

Population: all ages

adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in use during anesthesia

Population: all ages

adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in post-traumatic chest conditions

Population: all ages

adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in atelectasis due to mucous obstruction

Population: all ages

adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in tuberculosis

Population: all ages

adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in primary amyloidosis of the lung

Population: all ages

Indications & Usage

INDICATIONS AND USAGE Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) INDICATIONS AND USAGE Acetylcysteine, administered orally, is indicated as an antidote to prevent or lessen hepatic injury which may occur following the ingestion of a potentially hepatotoxic quantity of acetaminophen. It is essential to initiate treatment as soon as possible after the overdose and, in any case, within 24 hours of ingestion.

💙 Support Programs

View all →
Acetylcysteine
Hospira, Inc.
ACETYLCYSTEINE
Unknown

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.